Biogaia

Biogaia AAQS

The The AAQS of Biogaia (BIOG B.ST) as of Nov 11, 2026 is 9. In the previous year, The AAQS was 9.00 — a change of 0.00% (lower).

AAQS

9

YoY

0.00%

Last updated:

Biogaia has a current AAQS of 9.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Biogaia in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Biogaia AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
9.00 SEK
Jan 1, 2019
9.00 SEK
Jan 1, 2020
9.00 SEK
Jan 1, 2021
9.00 SEK
Jan 1, 2022
9.00 SEK
Jan 1, 2023
9.00 SEK
Jan 1, 2024
9.00 SEK
Jan 1, 2025
9.00 SEK
The Biogaia AAQS history
YEARAAQSYoY
90.00%
90.00%
90.00%
90.00%
90.00%
90.00%
90.00%
90.00%
90.00%
90.00%
90.00%
9—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biogaia Stock analysis

What does Biogaia do? BioGaia AB generates revenue through its probiotic product segments, primarily featuring Limosilactobacillus reuteri strains. The Paediatrics segment sells drops, gut health tablets, oral rehydration solutions, and cultures for licensee products. The Adult Health segment offers gut health tablets, oral health lozenges, and cultures integrated into dairy products by licensees. The Other segment includes royalties from development projects and revenue from CapAble's packaging solutions. Products are marketed globally to consumers seeking health benefits from probiotics, with licensees distributing branded items under agreements. The company targets health-conscious consumers through direct sales and licensed partnerships. Paediatrics products focus on infant and child health, while Adult Health products address digestive and oral wellness. CapAble, a subsidiary, contributes through packaging solutions, and royalties from development projects provide additional income streams. All segments operate under BioGaia's brand, leveraging documented health benefits of their probiotic strains. Biogaia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biogaia stock

The AAQS of Biogaia is 9 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Biogaia since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Biogaia

All Key Metrics — Biogaia